PHARMACEUTICAL PROCESSING | JANUARY/FEBRUARY 2015 7 ■
■ FIND PHARMACEUTICAL PROCESSING ON SOCIAL MEDIA
Twitter:@PharmProEditor facebook.com/pharmprocessing http://linkd.in/1oUxL1d http://bit.ly/1hfXqeP reddit.com/user/PharmPro/
RIGHT NOW ON PHARMPRO.COM
How the ‘Internet of Things’ is Poised
to Transform the World of Pharma
Tom Egan, Vice President, Industry
Services, PMMI, The Association
for Packaging and Processing
For pharmaceutical manufacturers, Io T
benefits include facilitating data analysis
and remote access to equipment, stream-
lining efficiencies and even preventing counterfeiting.
Read more here: http://bit.ly/1KCJayn
Massachusetts Attorney General-
Elect May Target Drug Companies
Attorney General-elect Maura Healey says she would consider
taking legal action against pharmaceutical companies to help
rein in prescription drug abuse that can lead to heroin addiction.
“The attention being given to the U.S. opioid abuse epidemic
by lawmakers and public officials is impressive. But the problem
is much bigger than what can be achieved through lawsuits
and penalties for over-marketing and over-prescribing. The
magnitude of the toll on society is still not fully appreciated…”
Read more here: http://bit.ly/1BZz8RO
Soaring Prices on Certain Generic
Drugs Cause Some Pharmacies to Close
Generic drugs are supposed to be a cheap and just as effective
alternative to high-priced name brand products. But a recent
trend has shown that the prices of generics are rising very quickly and the pace of insurance reimbursement has not kept pace.
Watch the video here: http://bit.ly/1BUFNim
New Diet Pill Serves Up 'Imaginary
Scientists are testing a new diet pill that tricks your body
into thinking that you've already eaten. The new drug works
differently than most diet pills which speed up your metabolism or serve as an appetite suppressant.
Watch the video here: http://bit.ly/1DBenA7
Surviving Pharma’s Uncertain
The average cost of developing an approved therapy is around
$4.3 billion dollars for companies with three or more approved
therapies, according to an analysis completed by Forbes.
Read more here: http://bit.ly/1IlvnKK
Biotech and Generic Drugs: 2015
Trends and Predictions
Ed Price, President of PCI
This is an industry that
knows extremes: We're
seeing a biotech bubble at
the same time we're seeing
companies squeezed out by
rising costs and fees necessary to just stay in business.
Pressures, including regulatory and dwindling competition,
are driving price increases among generics while at the same
time, there are drug shortages.
Read more here: http://bit.ly/14qILOd
Serialization: Don’t Wait Until the
Kevin Swartz, Senior Engineer, IPS; Tina Gushue,
Process Engineer, IPS
A reminder to pharma manufacturers, the Drug Supply
Chain Security Act (DSCSA) deadlines are quickly approaching. Have you planned for the implementation of
Transaction Documents for your packaged products and how
to introduce them into your supply chain?
Read more here: http://bit.ly/1w9WDTT